Immucell Corp /de/ ICCC US Equity☆

Immucell Corp /de/ (Nasdaq: ICCC), an SEC filer in In Vitro & In Vivo Diagnostic Substances, closed at $9.94, -0.8%, on 2026-08-28, with a market cap of $91M as of 2026-08-27, a return on equity of -3.8%, a net margin of -3.8% and 3-year sales growth of 14.2%. Institutional ownership, earnings history and filed financials are on the tabs below.